Supplemental Digital Content Table 1: Demographic, preoperative and postoperative characteristics of cases undergoing DSAEK after TASS
Cas e No.
Age (yea rs )
Se x
Preo p UDV A
Preo p IOP (mm Hg)
CCT (µm )
Duration betwee n TASS and DSAEK (months )
Preop Donor endothe lial cell count (cells/m m2)
Postop UDVA (at last follow up)
Postop CDVA (at last follow up)
Postop IOP (mm Hg) (at last follow up)
Anatom ical Outcom e (at last follow up)
Additional surgical procedures
Postop CCT ( µm) (at last follow up)
Postop donor thickness ( µm ) (at last follow up)
Postop specular (cells/mm2 ) (at last follow up)
% Endot helial cell loss (per year)
Follow up (mont hs)
1. 62 F HMC
F
18* 740 2 2550 PL PL 21** Failed
graf
Repeat DSAEK, penetrating keratoplasty, trabeculecto my
1340 - CNV - 24
2. 58 M 1/60 19 710 2.5 2750 FCCF FCCF 18* Failed
graf
Penetrating keratoplasty, trabeculecto my
1250 - CNV - 20
3. 68 F 1/60 15* 690 6 2880 6/36 6/18 18** GC 4+ None 580 122 1225 31.3% 22
4. 71 F FCCF 10 780 12 2670 6/24 6/12 16 GC 4+ None 555 121 1945 18.1% 18
5. 59 M 3/60 8 750 9 2700 6/12 6/9 14 GC 4+ None 565 114 1650 25.9% 18
6. 65 F FCCF 14 650 7 2430 6/18 6/9 17 GC 4+ None 575 94 1560 28.6% 15
7. 66 F FCCF 13 680 8 2510 6/18 6/12 18* GC 4+ None 580 87 1440 34.1% 15
8. 73 M 1/60 18* 720 10.5 2650 6/12 6/9 15** GC 4+ None 560 75 1880 21.8% 16
9. 55 M 2/60 16* 690 11 2450 6/24 6/18 12* GC 4+ None 540 110 1350 44.9% 12
10. 60 M 3/60 20 675 15 2300 6/12 6/12 13* GC 4+ None 550 90 1810 19.7% 13
11. 72 F HMC
F
12 680 12 2690 6/18 6/12 16 GC 4+ None 575 120 1980 22.6% 14
12. 75 M 1/60 17* 640 13 2720 6/12 6/9 15** GC 4+ None 590 60 1765 35.1% 12
13. 69 M 2/60 15 750 8 2320 6/9 6/9 14 GC 4+ None 535 66 1195 48.5% 12
14. 59 M 4/60 11 700 10 2820 6/12 6/9 10 GC 4+ None 564 53 2090 25.9% 12
Me an
± SD
65.1
±6.4
14.7
± 3.6
703.
9 ± 40.2
9.0 ± 3.8 2602.9
± 179.6
15.5 ± 2.8
668.5
± 266.5
92.7 ± 25 1657.5 ± 303.1
29.7 ± 9.6
15.9 ± 4.0
DSAEK-Descemet Stripping Automated Endothelial Keratoplasty, TASS- Toxic Anterior Segment Syndrome, UDVA- Uncorrected distance visual acuity, IOP- intraocular pressure, CCT- central corneal thickness, CDVA- corrected distance visual acuity, M- male, F- female, HMCF- perception of hand movements close to face, FCCF- counting fingers close to face, PL- perception of light, GC- graf clarity, CNV- counts not captured, * IOP controlled on two topical antiglaucoma medications
(Timolol+Brimonidine), **IOP controlled on three topical antiglaucoma medications (Timolol+Brimonidine+Brinzolamide)
